| Not Yet Recruiting | the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines NCT07338851 | China National Biotec Group Company Limited | — |
| Not Yet Recruiting | Study of Concomitant Administration of the sIPV and DTaP or MMR NCT06920069 | Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 4 |
| Not Yet Recruiting | Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pent NCT06748612 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 4 |
| Recruiting | Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants NCT06605755 | Jiangsu Province Centers for Disease Control and Prevention | N/A |
| Not Yet Recruiting | Phase IV Study of Concomitant Administration of the sIPV and HepA NCT06460545 | Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 4 |
| Active Not Recruiting | A Tool Kit to Improve Vaccine Confidence in the Philippines NCT06218368 | University of Toronto | N/A |
| Completed | Evaluation of Fatigue Severity, Mood, and Quality of Life in Post-Polio Syndrome NCT06162104 | Istanbul Physical Medicine Rehabilitation Training and Research Hospital | — |
| Unknown | Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV NCT06114810 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 4 |
| Unknown | Immunogenicity of After Primary Immunization and Booster Immunization of sIPV NCT06058429 | Sinovac Biotech Co., Ltd | — |
| Completed | A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine NCT05850364 | Sinovac Biotech Co., Ltd | Phase 3 |
| Completed | Community Engagement and Conditional Incentives to Accelerate Polio NCT05721274 | Aga Khan University | N/A |
| Unknown | Effect of Digital Payment to Campaign Health Workers on Vaccination Coverage NCT05684081 | Makerere University | N/A |
| Completed | Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in NCT04576910 | Zhejiang Provincial Center for Disease Control and Prevention | Phase 4 |
| Completed | Comparison of Immunogenicity of Inactivated Poliovirus Vaccine (IPV) Administered Intramuscularly or Intraderm NCT04027036 | Instituto Nacional de Saúde, Mozambique | Phase 2 |
| Completed | Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute NCT05083039 | Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products | — |
| Completed | Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge S NCT04232943 | PATH | Phase 1 |
| Unknown | Environmental Surveillance (ES) for Polio and AMR Using the TaqMan Array Card NCT03818477 | University of Virginia | — |
| Completed | Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Gi NCT03922061 | University of Vermont | Phase 1 |
| Completed | Evaluation of an Infant Immunization Encouragement Program in Nigeria NCT03870061 | GiveWell | N/A |
| Unknown | Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan NCT03341195 | Aga Khan University | N/A |
| Completed | Evaluation of Integrating MIYCN Interventions in Existing CGPP of PCI NCT03368885 | FHI 360 | N/A |
| Completed | Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib) NCT04264546 | Jiangsu Province Centers for Disease Control and Prevention | Phase 1 / Phase 2 |
| Completed | Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine NCT04264598 | Jiangsu Province Centers for Disease Control and Prevention | Phase 1 |
| Completed | Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in NCT03147560 | Zhejiang Provincial Center for Disease Control and Prevention | Phase 4 |
| Completed | DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infect NCT02817451 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda NCT04177485 | Centers for Disease Control and Prevention | N/A |
| Completed | OPV Transmissibility in Communities After Cessation of Routine OPV Immunization NCT02376374 | Stanford University | N/A |
| Withdrawn | Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Wes NCT01810731 | Centers for Disease Control and Prevention | Phase 2 / Phase 3 |
| Completed | Safety Study of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) in Inf NCT02111135 | Vaxtrials S.A. | Phase 2 |
| Completed | Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan NCT02005536 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Unknown | To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Interventio NCT01908114 | Aga Khan University | Phase 4 |
| Unknown | Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine NCT01841671 | University of Chile | Phase 4 |
| Completed | Diarrhea and Bivalent Oral Polio Vaccine Immunity NCT01559636 | Centers for Disease Control and Prevention | N/A |
| Completed | Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 and bOPV 1,3 NCT01586572 | Aga Khan University | N/A |
| Completed | Evaluation of Buffer on Immune Response to Oral Polio Vaccine (OPV) in Bangladesh NCT01579825 | Johns Hopkins Bloomberg School of Public Health | N/A |
| Completed | Polio NID and Routine EPI Integration Trial Pakistan NCT01697280 | Aga Khan University | N/A |
| Completed | Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China NCT01491087 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis NCT01475539 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan NCT01389687 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age NCT01346293 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China NCT01278433 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | A Study of the Safety of IMOVAX Polio™ in China NCT01244464 | Sanofi | Phase 4 |
| Completed | Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease NCT00855855 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish NCT00619502 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine NCT00514059 | Norwegian Institute of Public Health | Phase 4 |
| Unknown | Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease NCT00932269 | Swedish Institute for Infectious Disease Control | — |
| Completed | Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai NCT00401531 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paedia NCT00362336 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Pr NCT00362427 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months NCT00315055 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV NCT00348387 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of Pentaxim™ in an Indian Population NCT00259337 | Sanofi | Phase 3 |
| Completed | Safety and Immune Response of Different Pediatric Combination Vaccines. NCT00255047 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ NCT00802867 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™ NCT00772928 | Sanofi | Phase 3 |
| Completed | Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines NCT00254917 | Sanofi | Phase 4 |
| Completed | Retrospective Survey of Safety of Fourth Dose Pentacel® in Children NCT00772369 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended NCT00662870 | Sanofi | Phase 3 |